Survival in patients with myelofibrosis (MF), median overall survival (OS) of 6 to 7 years, is shorter than that of the general population.1 MF is also associated with profound negative effects on quality of life.

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study / Guglielmelli P.; Ghirardi A.; Carobbio A.; Masciulli A.; Maccari C.; Mora B.; Rumi E.; Triguero A.; Finazzi M.C.; Pettersson H.; Paoli C.; Mannelli F.; Vanni D.; Rambaldi A.; Passamonti F.; Alvarez-Larran A.; Andreasson B.; Vannucchi A.M.; Barbui T.. - In: BLOOD ADVANCES. - ISSN 2473-9529. - ELETTRONICO. - 6:(2022), pp. 373-375. [10.1182/bloodadvances.2021006006]

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study

Guglielmelli P.;Ghirardi A.;Maccari C.;Paoli C.;Mannelli F.;Vannucchi A. M.;
2022

Abstract

Survival in patients with myelofibrosis (MF), median overall survival (OS) of 6 to 7 years, is shorter than that of the general population.1 MF is also associated with profound negative effects on quality of life.
2022
6
373
375
Guglielmelli P.; Ghirardi A.; Carobbio A.; Masciulli A.; Maccari C.; Mora B.; Rumi E.; Triguero A.; Finazzi M.C.; Pettersson H.; Paoli C.; Mannelli F....espandi
File in questo prodotto:
File Dimensione Formato  
advancesADV2021006006 (1).pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 621.88 kB
Formato Adobe PDF
621.88 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1257207
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 41
social impact